Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of the study is to see if apricitabine or tipranavir affect the levels of each other in the blood (pharmacokinetic interaction) when they are dosed together.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Avexa
• Treatments: Tipranavir

Criteria

Inclusion Criteria:

• healthy males 18-40 years old

• non-smokers

• no clinically significant medical history

Exclusion Criteria:

• current or relevant previous medical history of significance

• hepatitis B, hepatitis C, or HIV positive

• current use of prescription or OTC medications

• use of illicit substances or alcohol (>14 drinks/week)